Business Context and Reporting Period
Company: Organigram Holdings Inc. (Foreign Private Issuer)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and nine months ended June 30, 2024
Filing Date: August 13, 2024
This filing serves as a cover document submitting the Management's Discussion and Analysis (MD&A), Condensed Consolidated Interim Unaudited Financial Statements, and a News Release regarding the company's results for the period ended June 30, 2024.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. The following metrics are referenced as being contained in the attached exhibits but are not disclosed in this text:
- Revenue: Not provided in text (see Exhibit 99.2 and 99.5).
- Profit/Loss: Not provided in text (see Exhibit 99.2 and 99.5).
- Cash Flow: Not provided in text (see Exhibit 99.2).
- Margins: Not provided in text (see Exhibit 99.1).
- Debt and Liquidity: Not provided in text (see Exhibit 99.2).
Material Changes
The filing text does not provide specific details on material changes versus prior periods. Investors must refer to Exhibit 99.1 (MD&A) and Exhibit 99.5 (News Release) for comparative analysis of the three and nine-month periods.
Guidance, Outlook, and Risks
Specific guidance, management commentary, risk factors, and contingencies are not detailed in this cover document. These items are expected to be addressed in the attached Management's Discussion and Analysis (Exhibit 99.1) and the News Release (Exhibit 99.5).
Investor Verification Checklist
- Review Exhibit 99.2 for the actual Condensed Consolidated Interim Unaudited Financial Statements to verify revenue, net income, and cash position.
- Consult Exhibit 99.1 for Management's Discussion and Analysis to understand the drivers of financial performance and liquidity.
- Read Exhibit 99.5 (News Release) for the official press announcement of results and any forward-looking statements.
- Verify the certifications signed by the Chief Executive Officer and Chief Financial Officer in Exhibits 99.3 and 99.4.